UMMS Affiliation

Commonwealth Medicine, Clinical Pharmacy Services

Date

8-12-2011

Document Type

Technical Report

Disciplines

Health Services Administration | Health Services Research | Pharmacy and Pharmaceutical Sciences

Abstract

Pipeline PredictorRx™ evaluates new drugs, expected to have a significant clinical or financial impact when approved by the FDA, and compares them to current therapies.

This UMass Medical School model, entirely independent of drug company interests, goes beyond detailing pharmacy outcomes for pipeline drugs — we also examine the potential for avoiding hospitalization and other medical costs.

Keywords

Pipeline PredictorRx™, drug evaluation, drug impact, pipeline drugs

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.